NCT06684327View on ClinicalTrials.gov

Multi-cohort, Single-arm Phase II Study of Albumin-paclitaxel, Ifosfamide, and Cisplatin in the Treatment of Rare Advanced Tumors

PHASE2RecruitingINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

November 30, 2024

Primary Completion Date

December 30, 2026

Study Completion Date

December 30, 2027

Conditions

Paget Disease, ExtramammaryRhabdomyosarcomaTesticular CancerPenile CancerUrachal Cancer

Interventions

DRUG

Albumin-paclitaxel Injection

Participant will receive albumin-paclitaxel 260mg/m2 d1, isocyclophosphamide 1500mg/m2 d2-5, and cisplatin 25mg/m2 d2-5 every 21 days until disease progression, intolerable toxicity, or full 6 cycles of treatment, whichever occurs first.

Trial Locations (1)

200032

RECRUITING

Fudan University Cancer Hospital, Shanghai

All Listed Sponsors

lead

Fudan University

OTHER